The startup has raised $16 million in a Series A round led by Celesta Capital, with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. The funds will be used to expand into the U.S. and scale its business in India. OneCell aims to reach over 1,000 oncologists and a million patients in the near term.
Key takeaways:
- OneCell Diagnostics, a genomics-based startup, aims to help cancer survivors limit reoccurrence instances through its proprietary cell biopsy technology. The startup has developed a blood-based biopsy testing that helps detect cancer’s reoccurrence through circulating tumor cells.
- The startup has also developed an app called iCare, which works as a precision oncology console to help oncologists interpret test reports using AI and machine learning. OneCell has developed a proprietary glass bead that uses antibodies and has an affinity toward cancer cells.
- OneCell operates under the B2B2C model, offering its biopsy testing to patients through oncologists and hospitals in India. It plans to start its business in the U.S. after over 2.5 years of serving India by working with biotech and biopharma companies.
- OneCell has raised $16 million in an oversubscribed Series A round led by Celesta Capital. The fresh capital will help OneCell expand into the U.S. and scale its business in India, aiming to reach over 1,000 oncologists and a million patients in the near term.